This is a very rare type of non-cancerous (benign) tumor that grows on the lining of your lung (pleura). It's not related to cancer or asbestos.
Every report comes from a Lived member, sent anonymously.
Have you had Video-Assisted Thoracic Surgery for Pleural Solitary Fibrous Tumor?
A pleural solitary fibrous tumor is a rare growth that starts in the pleura, the thin lining that covers the lungs and the inside of the chest wall. It forms from fibroblasts, the cells that make connective tissue, and usually grows as a single, well-defined mass. Some hang from the lung surface on a narrow stalk, while others sit flat against the lining. Most of these tumors are benign and grow slowly, but a smaller group behaves more aggressively: they can come back after removal or, less often, spread to other parts of the body. Because the tumor grows slowly, many people have no symptoms and learn about it only when a chest X-ray or computed tomography (CT) scan is done for another reason. A large tumor can press on the lung and cause cough, shortness of breath or chest pain. This tumor used to be called benign or localized fibrous mesothelioma, and that old name still appears in some records. It is not mesothelioma, the asbestos-related cancer of the chest lining, and it is treated and followed very differently.
No cause or risk factor has been established. Unlike mesothelioma, it has not been linked to asbestos, and smoking and radiation have not been shown to raise risk either. It is most often found in middle-aged and older adults and affects men and women about equally. Researchers have found that these tumors carry a characteristic change inside the tumor cells, in which two genes (NAB2 and STAT6) become fused and drive the growth. This change arises in the tumor itself. It is not inherited, so it does not mean relatives are at higher risk.
The tumor is usually first seen on a chest X-ray or CT scan, often by chance. CT shows its size, where it attaches and whether it is pushing on or growing into nearby structures. Magnetic resonance imaging (MRI) may be added when the tumor sits against the chest wall, spine or diaphragm, and a positron emission tomography (PET) scan, which shows how actively tissue uses sugar, is sometimes used, although neither can reliably tell a benign tumor from an aggressive one. A needle biopsy is not always needed before surgery. A small sample can miss the tumor's features, so when imaging strongly suggests a removable pleural tumor, surgeons often remove it and make the diagnosis from the whole specimen. A biopsy is more useful when the tumor cannot be removed or the diagnosis is unclear. The diagnosis is confirmed by a pathologist, who examines the tissue under a microscope and tests it for STAT6, a protein marker that reflects the tumor's gene change. The pathologist also looks at how quickly the cells are dividing, whether any tissue has died (necrosis) and the tumor's size. These features help estimate the risk of the tumor coming back and shape the follow-up plan.
Surgery to remove the whole tumor with a rim of healthy tissue is the main treatment, and for most people it is the only treatment needed. A tumor on a stalk can often be removed with a small wedge of lung. A tumor that sits flat or arises from the chest wall lining may need a larger operation, occasionally including part of the lung, ribs or diaphragm. Smaller tumors can often be removed through keyhole (thoracoscopic or robotic) surgery, while very large ones usually need an open operation. Bleeding and breathing problems are the main risks of surgery, especially with large tumors, and some teams block the tumor's feeding blood vessels beforehand to reduce bleeding. Radiation after surgery may be offered when the tumor had high-risk features or could not be fully removed. It can help control the tumor in the chest, but it has not been shown to help people live longer. If the tumor returns in the same area, another operation is often possible. For tumors that cannot be removed or have spread, standard chemotherapy rarely shrinks them. Medicines that block the growth of the tumor's blood supply, such as pazopanib (Votrient), a daily pill approved for advanced soft tissue sarcoma, have controlled the disease in many people in small trials. Because the tumor is rare, care is best planned with a team experienced in sarcomas.
After a complete operation, most people recover well and return to normal activities, and long-term survival is high, particularly for benign tumors. Recovery time depends mainly on the size of the operation: a few days in hospital after keyhole surgery, longer after an open or extended one. The tumor can come back even after it has been fully removed. In surgical studies this happens in roughly 5 to 17 percent of people overall, and more often after tumors with aggressive features. Most recurrences appear within the first two years, but some have been found more than a decade later. For that reason, follow-up usually involves a CT scan about every six months for the first two years and then once a year, with closer and longer monitoring when the tumor had high-risk features. Finding a recurrence early matters because a local regrowth can often be removed again. In people whose tumor was causing low blood sugar, removing it usually resolves the problem.
See a clinician if a scan shows a mass in the chest lining, or if you develop a lasting cough, increasing shortness of breath, chest pain or cough with blood. After treatment, report any of these new symptoms, along with unexplained weight loss or new bone pain, rather than waiting for the next scheduled scan. Rarely, this tumor makes a hormone-like substance that drives blood sugar down. Episodes of shaking, sweating, confusion or dizziness, especially when you have not eaten, should be raised with your care team right away so your blood sugar can be checked. If someone passes out, has a seizure or cannot be woken, call 911.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Pleural Solitary Fibrous Tumor is like, what's helped you, or ask the community a question.